retifanlimab
Selected indexed studies
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. (Lancet, 2025) [PMID:40517007]
- POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. (Front Oncol, 2022) [PMID:36091159]
- Retifanlimab: First Approval. (Drugs, 2023) [PMID:37184754]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. (2025) pubmed
- POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. (2022) pubmed
- Retifanlimab: First Approval. (2023) pubmed
- Retifanlimab. (2006) pubmed
- A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). (2022) pubmed
- Retifanlimab-dlwr. (2023) pubmed
- Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). (2025) pubmed
- Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study. (2025) pubmed
- Retifanlimab (Zynyz) for anal cancer. (2025) pubmed
- Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. (2025) pubmed